Welcome to our dedicated page for Ovid Therapeutics SEC filings (Ticker: OVID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ovid Therapeutics Inc. (Nasdaq: OVID) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Ovid is a New York‑based biopharmaceutical company developing small molecule medicines for brain conditions driven by neuronal hyperexcitability, and its filings offer detailed insight into this strategy, its capital structure and governance.
Investors can review current reports on Form 8‑K, where Ovid reports material events such as positive Phase 1 data for OV329 and OV350, leadership succession plans, private placement financing agreements involving Series B convertible preferred stock and warrants, and transactions like the sale of future ganaxolone royalty rights to Immedica Pharma AB. Other 8‑K items describe Nasdaq listing compliance developments, including bid price notifications, transfers to the Nasdaq Capital Market and subsequent confirmations of regained compliance.
Definitive proxy statements on Schedule 14A, such as the company’s special meeting materials, outline proposals to increase authorized common shares, approve conversions of preferred stock and warrant exercises related to PIPE financings, and authorize reverse stock split ranges. These documents also describe how Ovid seeks stockholder approval for securities issuances under Nasdaq listing rules.
Through Stock Titan, users can monitor Ovid’s real‑time filing activity from EDGAR, including 10‑K and 10‑Q reports when available, as well as Forms 3, 4 and 5 that disclose insider holdings and transactions. AI‑powered tools help summarize lengthy filings, highlight key sections on clinical pipeline strategy, financing terms, listing status and executive arrangements, and make it easier to interpret complex legal and financial language.
For anyone analyzing OVID stock, this filings page serves as a centralized view of Ovid Therapeutics’ official regulatory record, spanning clinical updates, capital markets transactions, governance decisions and listing‑related communications.
Ovid Therapeutics Executive Chairman Jeremy M. Levin exercised a Series A warrant to acquire 47,333 shares of Common Stock at $1.40 per share. Following the exercise, he directly holds 3,735,048 shares of Common Stock.
The filing also reports 35,461 shares of Common Stock held indirectly through Divo Holdings, LLC, managed by Levin’s spouse. Levin expressly disclaims beneficial ownership of the shares held by Divo.
Ovid Therapeutics Inc. is a Delaware-based biopharmaceutical company focused on small molecule medicines for brain disorders driven by neuronal hyperexcitability, including epilepsies, psychoses, schizophrenia and mood disorders. Its strategy targets fundamental CNS mechanisms such as GABA-aminotransferase inhibition and direct activation of potassium-chloride cotransporter 2 (KCC2).
The lead seizure program, OV329, is a next-generation GABA-AT inhibitor intended as a safer, more potent alternative to vigabatrin for drug‑resistant epilepsies, tuberous sclerosis complex seizures and infantile spasms. Phase 1 data in healthy volunteers showed favorable safety, biomarker evidence of increased GABAergic activity and no observed retinal accumulation in animal models at expected therapeutic doses.
Ovid’s KCC2 portfolio, in‑licensed from AstraZeneca, includes more than 100 small molecules and the oral candidate OV4071, with a Phase 1 trial planned for the second quarter of 2026 to explore applications in psychosis and mood disorders. The company also holds economic rights from a ganaxolone license to Immedica via Marinus, including a $7.0 million cash payment replacing royalties. As of June 30, 2025, non‑affiliate common stock market value was about $22.2 million, and as of March 16, 2026 there were 131,874,634 common shares outstanding.
Ovid Therapeutics entered a private placement financing, agreeing to sell 19,154,321 common shares at $2.01 and pre-funded warrants for up to 10,701,710 shares at $2.009 each, for expected gross proceeds of $60.0 million before fees. The company signed a registration rights agreement to register these securities for resale shortly after closing.
Ovid reported favorable 7 mg Phase 1 data for OV329 and plans a Phase 2 trial in treatment-resistant focal onset seizures plus new studies in tuberous sclerosis complex seizures and infantile spasms. OV4071 received clearance to begin Phase 1 in Australia, triggering a 30-day exercise window for Series A warrants that could add up to $53.9 million in gross proceeds.
As of December 31, 2025, Ovid held $90.4 million in cash, cash equivalents and marketable securities and reported 2025 revenue of $7.3 million, total operating expenses of $49.7 million and a net loss of $17.4 million, while fourth quarter 2025 net income was $9.7 million driven mainly by a fair value gain on an equity investment.
Ovid Therapeutics President and CEO Margaret A. Alexander reported two equity transactions. She received an employee stock option for 1,435,000 shares at an exercise price of $0.00, which will vest in 48 equal monthly installments starting on March 20, 2026, contingent on continued service.
Separately, she sold 11,656 shares of common stock at a weighted average price of $1.45 per share. According to the disclosure, this was a mandatory “sell to cover” transaction to satisfy statutory tax withholding from vesting restricted stock units, and is described as not a discretionary sale. After the sale, she directly owned 61,750 common shares and held the newly granted option for 1,435,000 shares.
Ovid Therapeutics Inc. director Stelios Papadopoulos received a grant of stock options covering 65,000 shares on February 26, 2026. These options have an exercise price of $0.00 per share, meaning they were awarded at no cost to him when granted.
The option grant will vest in full on February 26, 2027, provided he remains in continuous service with the company through that date. After this grant, he holds options on 65,000 shares directly, aligning his compensation more closely with the company’s future performance.
Ovid Therapeutics Inc. reported that director Jeremy M. Levin received a grant of employee stock options covering 957,000 shares of Ovid common stock. These options were awarded as a form of compensation, not through an open-market purchase or sale.
According to the terms, the options will vest in 48 equal monthly installments starting on March 20, 2026. Vesting is conditioned on Levin’s continued service to the company through each vesting date, meaning he earns the right to exercise a portion of the options each month over a four-year period.
Fitzgerald Kevin Joseph reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics Inc. director Kevin Joseph Fitzgerald reported receiving an employee stock option grant covering 65,000 shares of common stock. The option was awarded on February 26, 2026 and is scheduled to vest in full on February 26, 2027, provided he remains in continuous service through that date.
Friedman Bart reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics Inc. director Bart Friedman reported receiving an equity award in the form of an employee stock option covering 65,000 shares. The option was granted at no cost on February 26, 2026 and will vest in full on February 26, 2027, provided he remains in continuous service through that date.
DUNCAN BARBARA GAYLE reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics director Barbara Gayle Duncan received a grant of employee stock options covering 65,000 shares on February 26, 2026. The options have a stated price of $0.0000 per share and will vest in full on February 26, 2027, subject to her continuous service through that vesting date.
Bernstein Karen reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics director Karen Bernstein was granted employee stock options covering 65,000 shares of Ovid common stock. The award was made on February 26, 2026 and is reported at a grant price of $0.00 per share in this filing.
According to the terms, the option will vest in full on February 26, 2027, as long as Bernstein continues to provide service to the company through that date. After vesting, the option will become exercisable for the underlying shares, subject to the company’s equity plan and any applicable restrictions.